{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:31:35Z","timestamp":1781519495866,"version":"3.54.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006389","name":"University of Geneva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The ATN model represents a research framework used to classify subjects based on the presence or absence of Alzheimer\u2019s disease (AD) pathology through biomarkers for amyloid (A), tau (T), and neurodegeneration (N). The aim of this study was to assess the relationship between ATN profiles defined through imaging and cognitive decline in a memory clinic cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One hundred-eight patients from the memory clinic of Geneva University Hospitals underwent complete clinical and neuropsychological evaluation at baseline and 23\u2009\u00b1\u20095\u00a0months after inclusion, magnetic resonance imaging, amyloid and tau PET scans. ATN profiles were divided into four groups: normal, AD pathological change (AD-PC: A\u2009+\u2009T-N-, A\u2009+\u2009T-N\u2009+), AD pathology (AD-P: A\u2009+\u2009T\u2009+\u2009N-, A\u2009+\u2009T\u2009+\u2009N\u2009+), and suspected non-AD pathology (SNAP: A-T\u2009+\u2009N-, A-T-N\u2009+\u2009, A-T\u2009+\u2009N\u2009+).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mini-Mental State Examination (MMSE) scores were significantly different among groups, both at baseline and follow-up, with the normal group having higher average MMSE scores than the other groups. MMSE scores changed significantly after 2\u00a0years only in AD-PC and AD-P groups. AD-P profile classification also had the largest number of decliners at follow-up (55%) and the steepest global cognitive decline compared to the normal group. Cox regression showed that participants within the AD-P group had a higher risk of cognitive decline (HR\u2009=\u20096.15, CI\u2009=\u20092.59\u201314.59), followed by AD-PC (HR\u2009=\u20093.16, CI\u2009=\u20091.17\u20138.52).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Of the different group classifications, AD-P was found to have the most significant effect on cognitive decline over a period of 2\u00a0years, highlighting the value of both amyloid and tau PET molecular imaging as prognostic imaging biomarkers in clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06311-3","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T04:02:24Z","timestamp":1687752144000},"page":"3313-3323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prognostic value of imaging-based ATN profiles in a memory clinic cohort"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3033-8817","authenticated-orcid":false,"given":"D\u00e9bora E.","family":"Peretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ribaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-5129","authenticated-orcid":false,"given":"Max","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Chicherio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-1753","authenticated-orcid":false,"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-698X","authenticated-orcid":false,"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"6311_CR1","doi-asserted-by":"publisher","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia [Internet]. 2018;14:535\u201362. Available from: https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"6311_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2010","unstructured":"Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9:119\u201328.","journal-title":"Lancet Neurol"},{"key":"6311_CR3","doi-asserted-by":"publisher","unstructured":"Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, et al. ATN classification and clinical progression in subjective cognitive decline. Neurology [Internet]. 2020;95:e46\u201358. Available from: https:\/\/doi.org\/10.1212\/WNL.0000000000009724.","DOI":"10.1212\/WNL.0000000000009724"},{"key":"6311_CR4","doi-asserted-by":"publisher","unstructured":"Ebenau JL, Pelkmans W, Verberk IMW, Verfaillie S, van den Bosch KA, van Leeuwenstijn M, et al. Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive decline. Neurology [Internet]. 2022;0:https:\/\/doi.org\/10.1212\/WNL.0000000000200035. Available from: https:\/\/doi.org\/10.1212\/WNL.0000000000200035.","DOI":"10.1212\/WNL.0000000000200035 10.1212\/WNL.0000000000200035"},{"key":"6311_CR5","doi-asserted-by":"publisher","unstructured":"Jack CR, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al. Associations of amyloid, Tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA [Internet]. 2019;321:2316. Available from: https:\/\/doi.org\/10.1001\/jama.2019.7437.","DOI":"10.1001\/jama.2019.7437"},{"key":"6311_CR6","doi-asserted-by":"publisher","unstructured":"Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, et al. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology [Internet]. 2019;92:e1567\u201379. Available from: https:\/\/doi.org\/10.1212\/WNL.0000000000007248.","DOI":"10.1212\/WNL.0000000000007248"},{"key":"6311_CR7","doi-asserted-by":"publisher","unstructured":"Delmotte K, Schaeverbeke J, Poesen K, Vandenberghe R. Prognostic value of amyloid\/tau\/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer\u2019s disease. Alzheimers Res Ther [Internet]. 2021;13:84. Available from: https:\/\/doi.org\/10.1186\/s13195-021-00817-4.","DOI":"10.1186\/s13195-021-00817-4"},{"key":"6311_CR8","doi-asserted-by":"publisher","unstructured":"Bucci M, Chiotis K, Nordberg A. Alzheimer\u2019s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol Psychiatry [Internet]. 2021;26:5888\u201398. Available from: https:\/\/doi.org\/10.1038\/s41380-021-01263-2.","DOI":"10.1038\/s41380-021-01263-2"},{"key":"6311_CR9","doi-asserted-by":"publisher","unstructured":"van de Beek M, Ooms FAH, Ebenau JL, Barkhof F, Scheltens P, Teunissen CE, et al. Association of the ATN research framework with clinical profile, cognitive decline, and mortality in patients with dementia with Lewy bodies. Neurology [Internet]. 2022;98:e1262\u201372. Available from: https:\/\/doi.org\/10.1212\/WNL.0000000000200048.","DOI":"10.1212\/WNL.0000000000200048"},{"key":"6311_CR10","doi-asserted-by":"publisher","unstructured":"Cullen NC, Leuzy A, Janelidze S, Palmqvist S, Svenningsson AL, Stomrud E, et al. Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun [Internet]. 2021;12:3555. Available from: https:\/\/doi.org\/10.1038\/s41467-021-23746-0.","DOI":"10.1038\/s41467-021-23746-0"},{"key":"6311_CR11","doi-asserted-by":"publisher","unstructured":"Ebenau JL, Visser D, Kroeze LA, van Leeuwenstijn MSSA, van Harten AC, Windhorst AD, et al. Longitudinal change in ATN biomarkers in cognitively normal individuals. Alzheimers Res Ther [Internet]. 2022;14:124. Available from: https:\/\/doi.org\/10.1186\/s13195-022-01069-6..","DOI":"10.1186\/s13195-022-01069-6."},{"key":"6311_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13195-020-00612-7","volume":"12","author":"PNE Young","year":"2020","unstructured":"Young PNE, Estarellas M, Coomans E, Srikrishna M, Beaumont H, Maass A, et al. Imaging biomarkers in neurodegeneration: current and future practices. Alzheimers Res Ther. 2020;12:49.","journal-title":"Alzheimers Res Ther"},{"key":"6311_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-021-00846-z","volume":"13","author":"F Ribaldi","year":"2021","unstructured":"Ribaldi F, Chicherio C, Altomare D, Martins M, Tomczyk S, Jelescu I, et al. Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design. Alzheimers Res Ther. 2021;13:105.","journal-title":"Alzheimers Res Ther"},{"key":"6311_CR14","doi-asserted-by":"publisher","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association Workgroups on Diagnostic Guidelines for Alzheimer\u2019s Disease. Focus (Madison) [Internet]. 2013;11:96\u2013106. Available from: https:\/\/doi.org\/10.1176\/appi.focus.11.1.96.","DOI":"10.1176\/appi.focus.11.1.96"},{"key":"6311_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dementia. 2011;7:263\u20139.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"6311_CR16","doi-asserted-by":"publisher","unstructured":"Pangman VC, Sloan J, Guse L. An examination of psychometric properties of the Mini-Mental State Examination and the Standardized Mini-Mental State Examination: implications for clinical practice. Applied Nursing Research [Internet]. 2000;13:209\u201313. Available from: https:\/\/doi.org\/10.1053\/apnr.2000.9231.","DOI":"10.1053\/apnr.2000.9231"},{"key":"6311_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1212\/WNL.0000000000001376","volume":"84","author":"LS Schneider","year":"2015","unstructured":"Schneider LS, Kennedy RE, Wang G, Cutter GR. Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology. 2015;84:1121\u20137.","journal-title":"Neurology"},{"key":"6311_CR18","doi-asserted-by":"publisher","unstructured":"Jovicich J, Marizzoni M, Sala-Llonch R, Bosch B, Bartr\u00e9s-Faz D, Arnold J, et al. Brain morphometry reproducibility in multi-center 3T MRI studies: a comparison of cross-sectional and longitudinal segmentations. Neuroimage [Internet]. 2013;83:472\u201384. Available from: https:\/\/doi.org\/10.1016\/j.neuroimage.2013.05.007.","DOI":"10.1016\/j.neuroimage.2013.05.007"},{"key":"6311_CR19","doi-asserted-by":"publisher","unstructured":"Ashburner J, Friston KJ. Unified segmentation. Neuroimage [Internet]. 2005;26:839\u201351. Available from: https:\/\/doi.org\/10.1016\/j.neuroimage.2005.02.018.","DOI":"10.1016\/j.neuroimage.2005.02.018"},{"key":"6311_CR20","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl B. FreeSurfer Neuroimage. 2012;62:774\u201381.","journal-title":"FreeSurfer Neuroimage"},{"key":"6311_CR21","doi-asserted-by":"publisher","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer\u2019s & Dementia [Internet]. 2015;11:1. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","DOI":"10.1016\/j.jalz.2014.07.003"},{"key":"6311_CR22","unstructured":"Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer\u2019s disease. Am J Pathol [Internet]. 1989;135:309\u201319. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2675616."},{"key":"6311_CR23","first-page":"221","volume":"10","author":"AJ Schwarz","year":"2018","unstructured":"Schwarz AJ, Shcherbinin S, Slieker LJ, Risacher SL, Charil A, Irizarry MC, et al. Topographic staging of tau positron emission tomography images. DADM. 2018;10:221\u201331.","journal-title":"DADM."},{"key":"6311_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2019.116189","volume":"206","author":"ET Rolls","year":"2020","unstructured":"Rolls ET, Huang C-C, Lin C-P, Feng J, Joliot M. Automated anatomical labelling atlas 3. Neuroimage. 2020;206: 116189.","journal-title":"Neuroimage"},{"key":"6311_CR25","doi-asserted-by":"publisher","unstructured":"Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage [Internet]. 2002;15:273\u201389. Available from: https:\/\/doi.org\/10.1006\/nimg.2001.0978.","DOI":"10.1006\/nimg.2001.0978"},{"key":"6311_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuroimage.2017.07.050","volume":"161","author":"S Mishra","year":"2017","unstructured":"Mishra S, Gordon BA, Su Y, Christensen J, Friedrichsen K, Jackson K, et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. Neuroimage. 2017;161:171\u20138.","journal-title":"Neuroimage"},{"key":"6311_CR27","doi-asserted-by":"publisher","first-page":"e2233","DOI":"10.1212\/WNL.0000000000009485","volume":"94","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Leuzy A, Janelidze S, Palmqvist S, Stomrud E, Strandberg O, et al. The implications of different approaches to define AT(N) in Alzheimer disease. Neurology. 2020;94:e2233\u201344.","journal-title":"Neurology"},{"key":"6311_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack","year":"2017","unstructured":"Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimer\u2019s Dementia. 2017;13:205\u201316.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"6311_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3 G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Su\u00e1rez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11:1\u201312.","journal-title":"Alzheimers Res Ther"},{"key":"6311_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.29245\/2572.942X\/2016\/6.1059","volume":"1","author":"J Crary","year":"2016","unstructured":"Crary J. Primary age-related tauopathy and the amyloid cascade hypothesis: the exception that proves the rule? J Neurol Neuromed. 2016;1:53\u20137.","journal-title":"J Neurol Neuromed"},{"key":"6311_CR31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1076\/jcen.25.5.625.14576","volume":"25","author":"N Scarmeas","year":"2003","unstructured":"Scarmeas N, Stern Y. Cognitive reserve and lifestyle. J Clin Exp Neuropsychol. 2003;25:625\u201333.","journal-title":"J Clin Exp Neuropsychol"},{"key":"6311_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1474-4422(04)00878-6","volume":"3","author":"JA Luchsinger","year":"2004","unstructured":"Luchsinger JA, Mayeux R. Dietary factors and Alzheimer\u2019s disease. Lancet Neurol. 2004;3:579\u201387.","journal-title":"Lancet Neurol"},{"key":"6311_CR33","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1212\/01.WNL.0000140488.65299.53","volume":"63","author":"RS Wilson","year":"2004","unstructured":"Wilson RS, Li Y, Aggarwal NT, Barnes LL, McCann JJ, Gilley DW, et al. Education and the course of cognitive decline in Alzheimer disease. Neurology. 2004;63:1198\u2013202.","journal-title":"Neurology"},{"key":"6311_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev.publhealth.24.100901.141015","volume":"24","author":"SK Pope","year":"2003","unstructured":"Pope SK, Shue VM, Beck C. Will a healthy lifestyle help prevent Alzheimer\u2019s disease? Annu Rev Public Health. 2003;24:111\u201332.","journal-title":"Annu Rev Public Health"},{"key":"6311_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-017-0297-z","volume":"9","author":"M Crous-Bou","year":"2017","unstructured":"Crous-Bou M, Minguill\u00f3n C, Gramunt N, Molinuevo JL. Alzheimer\u2019s disease prevention: from risk factors to early intervention. Alzheimers Res Ther. 2017;9:71.","journal-title":"Alzheimers Res Ther"},{"key":"6311_CR36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00234-020-02562-1","volume":"63","author":"LL de Godoy","year":"2021","unstructured":"de Godoy LL, Alves CAPF, Saavedra JSM, Studart-Neto A, Nitrini R, da Costa LC, et al. Understanding brain resilience in superagers: a systematic review. Neuroradiology. 2021;63:663\u201383.","journal-title":"Neuroradiology"},{"key":"6311_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","volume":"23","author":"GB Frisoni","year":"2022","unstructured":"Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R, et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci. 2022;23:53\u201366.","journal-title":"Nat Rev Neurosci"},{"key":"6311_CR38","doi-asserted-by":"publisher","unstructured":"Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G, et al. Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging. Nat Aging [Internet]. 2022; Available from: https:\/\/doi.org\/10.1038\/s43587-022-00204-0.","DOI":"10.1038\/s43587-022-00204-0"},{"key":"6311_CR39","doi-asserted-by":"publisher","unstructured":"Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ. In vivo staging of regional amyloid deposition. Neurology [Internet]. 2017;89:2031\u20138. Available from: https:\/\/doi.org\/10.1212\/WNL.0000000000004643.","DOI":"10.1212\/WNL.0000000000004643"},{"key":"6311_CR40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389\u2013404.","journal-title":"Acta Neuropathol"},{"key":"6311_CR41","doi-asserted-by":"publisher","unstructured":"Biel D, Brendel M, Rubinski A, Buerger K, Janowitz D, Dichgans M, et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res Ther [Internet]. 2021;13:137. Available from: https:\/\/doi.org\/10.1186\/s13195-021-00880-x.","DOI":"10.1186\/s13195-021-00880-x"},{"issue":"17","key":"6311_CR42","doi-asserted-by":"publisher","first-page":"e1692","DOI":"10.1212\/WNL.0000000000200148","volume":"98","author":"LE Collij","year":"2022","unstructured":"Collij LE, Salvad\u00f3 G, Wottschel V, Mastenbroek SE, Schoenmakers P, Heeman F, et al. Spatial-temporal patterns of amyloid-\u03b2 accumulation: a subtype and stage inference model analysis. Neurology. Apr2022;98(17):e1692\u2013703. https:\/\/doi.org\/10.1212\/WNL.0000000000200148.","journal-title":"Neurology."},{"key":"6311_CR43","doi-asserted-by":"publisher","unstructured":"Jack CR, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, et al. Age-specific and sex-specific prevalence of cerebral \u03b2-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50\u201395 years: a cross-sectional study. Lancet Neurol [Internet]. 2017;16:435\u201344. Available from: https:\/\/doi.org\/10.1016\/S1474-4422(17)30077-7.","DOI":"10.1016\/S1474-4422(17)30077-7"},{"key":"6311_CR44","doi-asserted-by":"publisher","unstructured":"Peretti DE, V\u00e1llez Garc\u00eda D, Renken RJ, Reesink FE, Doorduin J, de Jong BM, et al. Alzheimer\u2019s disease pattern derived from relative cerebral flow as an alternative for the metabolic pattern using SSM\/PCA. EJNMMI Res [Internet]. 2022;12:37. Available from: https:\/\/doi.org\/10.1186\/s13550-022-00909-8.","DOI":"10.1186\/s13550-022-00909-8"},{"key":"6311_CR45","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1006\/nimg.2002.1208","volume":"17","author":"K Herholz","year":"2002","unstructured":"Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Fr\u00f6lich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302\u201316.","journal-title":"Neuroimage"},{"key":"6311_CR46","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow K, Hampel H. CSF markers for incipient Alzheimer\u2019s disease. Lancet Neurol. 2003;2:605\u201313.","journal-title":"Lancet Neurol"},{"key":"6311_CR47","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1177\/0271678X17732508","volume":"37","author":"SK Meles","year":"2017","unstructured":"Meles SK, Pagani M, Arnaldi D, De Carli F, Dessi B, Morbelli S, et al. The Alzheimer\u2019s disease metabolic brain pattern in mild cognitive impairment. J Cereb Blood Flow Metab. 2017;37:3643\u20138.","journal-title":"J Cereb Blood Flow Metab"},{"key":"6311_CR48","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1007\/s00259-017-3761-x","volume":"44","author":"M Pagani","year":"2017","unstructured":"Pagani M, Nobili F, Morbelli S, Arnaldi D, Giuliani A, \u00d6berg J, et al. Early identification of MCI converting to AD: a FDG PET study. Eur J Nucl Med Mol Imaging. 2017;44:2042\u201352.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6311_CR49","doi-asserted-by":"publisher","unstructured":"Morbelli S, Bauckneht M, Arnaldi D, Picco A, Pardini M, Brugnolo A, et al. 18F\u2013FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer\u2019s disease (AD) patients at the mild cognitive impairment (MCI) stage. Eur J Nucl Med Mol Imaging [Internet]. 2017;44:2073\u201383. Available from: https:\/\/doi.org\/10.1007\/s00259-017-3790-5.","DOI":"10.1007\/s00259-017-3790-5"},{"key":"6311_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2018.11.004","volume":"21","author":"F Albrecht","year":"2019","unstructured":"Albrecht F, Ballarini T, Neumann J, Schroeter ML. FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson\u2019s disease: a whole-brain multimodal imaging meta-analysis. Neuroimage Clin. 2019;21: 101594.","journal-title":"Neuroimage Clin"},{"key":"6311_CR51","doi-asserted-by":"crossref","unstructured":"Boccalini C, Ribaldi F, Hristovska I, Arnone A, Peretti D, Mu L, et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Accepted for publication at Alzheimer\u2019s & Dementia. 2023.","DOI":"10.1002\/alz.13355"},{"key":"6311_CR52","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A, Norton N, Fast T, Fr\u00f6lich L, Georges J, Holzapfel D, et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimer\u2019s Dement. 2023;19:658\u201370.","journal-title":"Alzheimer\u2019s Dement"},{"key":"6311_CR53","doi-asserted-by":"publisher","unstructured":"Bartels C, K\u00f6gel A, Schweda M, Wiltfang J, Pentzek M, Schicktanz S, et al. Use of cerebrospinal fluid biomarkers of Alzheimer\u2019s disease risk in mild cognitive impairment and subjective cognitive decline in routine clinical care in Germany. Journal of Alzheimer\u2019s Disease [Internet]. 2020;78:1137\u201348. Available from: https:\/\/doi.org\/10.3233\/JAD-200794.","DOI":"10.3233\/JAD-200794"},{"key":"6311_CR54","doi-asserted-by":"publisher","unstructured":"Ebenau JL, Pelkmans W, Verberk IMW, Verfaillie SCJ, van den Bosch KA, van Leeuwenstijn M, et al. Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive decline. Neurology [Internet]. 2022;98:e1315\u201326. Available from: \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000200035.","DOI":"10.1212\/WNL.0000000000200035"},{"key":"6311_CR55","doi-asserted-by":"publisher","unstructured":"Kivis\u00e4kk P, Magdamo C, Trombetta BA, Noori A, Kuo Y kai E, Chibnik LB, et al. Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. Brain Communications, 2022;4(4). https:\/\/doi.org\/10.1093\/braincomms\/fcac155.","DOI":"10.1093\/braincomms\/fcac155"},{"key":"6311_CR56","doi-asserted-by":"crossref","unstructured":"Altomare D, Stampacchia S, Ribaldi F, Tomczyk S, Chevalier C, Poulain G, et al. Plasma biomarkers for Alzheimer\u2019s disease: a field-test in a memory clinic. J Neurol Neurosurg Psychiatry. 2023.","DOI":"10.1136\/jnnp-2022-330619"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06311-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T07:03:55Z","timestamp":1695971035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06311-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6311"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06311-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"7 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local review board (Cantonal Research Ethics Commission, Geneva, Switzerland) approved the study, which has been conducted in concordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice. All subjects provided written informed consent to have collected data be used in research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided signed informed consent for participation in the study and for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VG received financial support for research and\/or speaker fees through her institution from Siemens Healthineers, GE Healthcare, and Novo Nordisk. Other authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}